A Phase 2a, Randomized, Double-Blind Placebo-controlled, Parallel-group Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Jan 2018
At a glance
- Drugs ASP 8062 (Primary)
- Indications Fibromyalgia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Astellas Pharma
- 04 Jan 2018 Planned End Date changed from 1 Apr 2018 to 1 Mar 2018.
- 04 Jan 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Mar 2018.
- 04 Jan 2018 Status changed from recruiting to active, no longer recruiting.